Literature DB >> 24688107

Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story.

Donald C Sheppard1, Paolo Campoli, Rafael F Duarte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24688107      PMCID： PMC3971068          DOI： 10.3324/haematol.2013.100263

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

5.  Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.

Authors:  Paolo Campoli; David S Perlin; Arnold S Kristof; Theodore C White; Scott G Filler; Donald C Sheppard
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

6.  Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein.

Authors:  Julie A Wasylnka; Margo M Moore
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Erja Chryssanthou; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

8.  Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Authors:  D Andes; K Marchillo; R Conklin; Gopal Krishna; Farkad Ezzet; Anthony Cacciapuoti; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

9.  Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.

Authors:  John E Conte; Jeffrey A Golden; Gopal Krishna; Marina McIver; Emily Little; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

Review 10.  Fungal invasion of normally non-phagocytic host cells.

Authors:  Scott G Filler; Donald C Sheppard
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823
View more
  4 in total

1.  Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

Review 2.  Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

3.  Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.

Authors:  Kim Vanstraelen; Juergen Prattes; Johan Maertens; Katrien Lagrou; Hélène Schoemans; Nele Peersman; Pieter Vermeersch; Koen Theunissen; Raf Mols; Patrick Augustijns; Pieter Annaert; Martin Hoenigl; Isabel Spriet
Journal:  Eur J Clin Pharmacol       Date:  2016-04-11       Impact factor: 2.953

4.  Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability.

Authors:  Martin Hoenigl; Robert Krause; David Lenczuk; Wilma Zinke-Cerwenka; Hildegard Greinix; Albert Wölfler; Jürgen Prattes; Ines Zollner-Schwetz; Thomas Valentin; Timothy C Lin; Andreas Meinitzer
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.